Antiviral Activity of AZD7295 in HCV Ca… | Clinical Trial

Key information

Conditions

Hepatitis C Blood-Borne Infections Communicable Diseases Digestive System Diseases Flaviviridae Infections Hepatitis Hepatitis, Viral, Human Infections Liver Diseases RNA Virus Infections Virus Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Prof Ed Gane

Auckland, New Zealand

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

HCV carrier

Exclusion criteria

concurrent medications

Treatment and study plan

AZD7295

Drug

700mg per day maximum

Placebo

Drug

matched placebo

Primary outcomes

Plasma AZD7295 concentrations and pharmacokinetics

Time frame: 5 days

Sponsors and collaborators

Lead sponsor

Arrow Therapeutics

Industry

Registry information

Official study title

A Randomised, DB, PC Study to Determine the PK, Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of AZD7295 in Otherwise Healthy Male and Female Hepatitis C Carriers With Compensated Liver Disease

Important dates

Study start: 2008
Primary completion: 2010
Study completion: 2010
First posted: Oct 29, 2008
Registry last updated: Mar 31, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed